Influvac Tetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202)

The vaccine contains inactivated influenza B virus antigens that stimulate the immune system. When injected, these antigens trigger B‑cell and T‑cell responses, leading to the production of specific antibodies and memory cells that can recognize and neutralize the live virus if the person is exposed in the future.

The dosage and administration schedule for Influvac Tetra are determined by the prescribing healthcare professional based on age, health status, and local immunization guidelines. The prescriber will decide the appropriate volume and timing for each individual patient.

Safety data for Influvac Tetra in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits and risks before vaccinating pregnant or breastfeeding individuals. In many regions, influenza vaccination is recommended during pregnancy to protect both mother and infant, but the decision should be made in consultation with a clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Influvac Tetra is a quadrivalent formulation that includes two influenza B strains, offering broader protection compared with trivalent vaccines that contain only one B strain. Its composition aligns with WHO recommendations for the current flu season, and it is administered intramuscularly like most other inactivated influenza vaccines.

Influvac Tetra must be stored at 2‑8 °C (refrigerated) and protected from light. The vial should remain in its original packaging, should not be frozen, and must be gently inverted if mixing is required. Do not shake the product vigorously, as this could affect its stability.

The vaccine is given by a single intramuscular injection, typically into the deltoid muscle of the upper arm. Administration is performed by a qualified healthcare professional using aseptic technique. The exact volume and needle size are determined by the prescriber based on patient age and body weight.

Serious adverse events are rare but may include anaphylaxis, Guillain‑Barré syndrome, and high‑grade fever lasting more than 48 hours. Any signs of severe allergic reaction, such as difficulty breathing, swelling of the face or throat, or rapid heartbeat, require immediate medical attention.

Individuals with a known severe allergy to any component of the vaccine, or who have experienced a previous severe reaction to an influenza vaccine, should not receive Influvac Tetra. Additionally, those with active moderate or severe febrile illness should defer vaccination until recovery.